Statistical analysis Statistical analyses were performed using SPSS (version 26
Gastrointestinal symptomsparticularly nausea, vomiting, diarrhoea, and constipationare the most frequently reported adverse effects of GLP-1 receptor agonists, occurring in 2050% of patients depending on the specific agent and dose according to clinical trials and SmPC data
It removes the single most commonly cited objection to GLP-1 initiation without requiring a patient to choose between needle-based treatment and no treatment at all
Many patients also describe the constant 'food noise' quieting down
It works by combining two medications, naltrexone and bupropion, which help to reduce hunger and control cravings, making it easier to follow a reduced-calorie diet and exercise plan
Categorisation of Nominated Substances: Because the evaluation process is extensive and ongoing, the FDA categorises "nominated" substances that have not yet reached a final decision